Page last updated: 2024-12-05

tolazoline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Tolazoline: A vasodilator that apparently has direct actions on blood vessels and also increases cardiac output. Tolazoline can interact to some degree with histamine, adrenergic, and cholinergic receptors, but the mechanisms of its therapeutic effects are not clear. It is used in treatment of persistent pulmonary hypertension of the newborn. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tolazoline : A member of the class of imidazoles that is 4,5-dihydro-1H-imidazole substituted by a benzyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5504
CHEMBL ID770
CHEBI ID28502
SCHEMBL ID34961
MeSH IDM0021628

Synonyms (127)

Synonym
BRD-K46211610-003-05-1
phenylmethylimidazoline
benzylimidazoline
dilatol asi
prefaxil
tolazolin
artonil
peripherine
2-benzyl-4,5-imidazoline
nsc-35110
benzidazol
kasimid
olitensol
divascol
vasimid
priscol
benzolin (vasodilator)
benzazoline
1h-imidazole,5-dihydro-2-(phenylmethyl)-
2-benzyl-2-imidazoline
2-imidazoline, 2-benzyl-
nsc35110
wln: t5m cn butj b1r
vasodilatan
vasodil
2-benzylimidazoline
benzolin
lambril
imidalin
priscoline
KBIO1_000328
DIVK1C_000328
2-(phenylmethyl)-4,5-dihydro-1h-imidazole
tolazolina [inn-spanish]
ciba 3259
benzalolin
tolazolinum [inn-latin]
benzolin (van)
einecs 200-448-9
tolazoline [inn:ban]
brn 0128757
nsc 35110
benzolin (vasodilator) (van)
SPECTRUM_000731
PRESTWICK2_000060
cas-59-97-2
NCGC00016271-01
BSPBIO_002068
BSPBIO_000219
2-benzyl-4,5-dihydro-1h-imidazole
1h-imidazole, 4,5-dihydro-2-(phenylmethyl)-
SPECTRUM5_001788
PRESTWICK3_000060
BPBIO1_000241
tolazoline
4,5-dihydro-2-(phenylmethyl)-1h-imidazole
C07147
59-98-3
DB00797
2-benzylimidazoline, 99%
CHEBI:28502 ,
KBIO2_003779
KBIOSS_001211
KBIO2_006347
KBIOGR_000793
KBIO2_001211
KBIO3_001568
PRESTWICK0_000060
NINDS_000328
SPECTRUM4_000357
SPECTRUM3_000594
SPBIO_002140
PRESTWICK1_000060
SPECTRUM2_001204
SPBIO_000988
IDI1_000328
NCGC00016271-03
NCGC00016271-02
AKOS000357643
CHEMBL770
L000960
D08614
tolazine [veterinary] (tn)
tolazoline (inn)
B3806
unii-chh9h12aq3
chh9h12aq3 ,
tolazolina
5-23-06-00488 (beilstein handbook reference)
tolazolinum
imidaline
FT-0603251
gtpl7310
STL362893
tolazoline [who-dd]
tolazoline [inn]
tolazoline [vandf]
FD7203
tolazoline [mi]
CS-3181
HY-A0066
AB00053555-12
BBL027502
SCHEMBL34961
2-benzyl-4,5-dihydro-1h-imidazole #
bdbm55436
2-benzyl-2-imidazoline;hydrochloride
2-benzyl-4,5-dihydro-1h-imidazole;hydrochloride
2-(phenylmethyl)-4,5-dihydro-1h-imidazole;hydrochloride
cid_6048
AB00053555_14
DTXSID3023683 ,
mfcd00005182
SBI-0051536.P003
Q413772
AS-49302
5-formylfyran-3-ylboronic?acid
BRD-K46211610-003-15-0
imidaline; nsc35110
2-benzyl-2-iminazoline hydrochloride
EN300-304854
dtxcid103683
m02ax02
tolazolinum (inn-latin)
tolazolina (inn-spanish)
tolazine (veterinary)
c04ab02

Research Excerpts

Overview

Tolazoline HCl appears to be an effective antagonist for xylazine HCl-ketamine HCl immobilization of wolves. Tolazoline is a potent vasodilator of arteries and veins and has a powerful effect on the pulmonary vasculature.

ExcerptReferenceRelevance
"Tolazoline is an α2-adrenergic receptor antagonist, used in veterinary medicine to antagonize the central nervous system depressant and cardiovascular effects of α2 receptor agonists. "( Pharmacokinetics and pharmacodynamic effects of tolazoline following intravenous administration to horses.
Casbeer, HC; Knych, HK, 2013
)
2.09
"Tolazoline is a potent vasodilator of arteries and veins and has a powerful effect on the pulmonary vasculature, reducing hypoxic pulmonary vasoconstriction and lowering pulmonary artery pressure. "( Pharmacokinetics of endobronchial tolazoline administration in dogs.
Barzilay, Z; Ben-Abraham, R; Eyal, O; Ezra, D; Manisterski, Y; Mayan, H; Paret, G; Vardi, A, 1999
)
2.03
"Tolazoline is a potent vasodilator of both arteries and veins and has a powerful effect on the pulmonary vasculature, reducing hypoxic pulmonary vasoconstriction and lowering pulmonary artery pressure. "( Endotracheal tolazoline: pharmacokinetics and pharmacodynamics in dogs.
Barzilay, Z; Ben-Abraham, R; Eyal, O; Ezra, D; Gilad, E; Mayan, H; Paret, G, 1999
)
2.12
"Tolazoline is an effective treatment of severe resistant hypoxemia in preterm infants who are already on vigorous ventilatory support."( Efficacy and safety of tolazoline for treatment of severe hypoxemia in extremely preterm infants.
Bada, HS; Korones, SB; Nuntnarumit, P; Yang, W, 2002
)
2.07
"Tolazoline appears to be an important pharmacologic agent for use in the postoperative care of infants with diaphragmatic hernia and associated hypoxemia and acidosis."( Use of tolazoline in newborn infants with diaphragmatic hernia and severe cardiopulmonary disease. A preliminary report.
Feldt, RH; Kleinberg, F; Moodie, DS; Telander, RL, 1978
)
1.43
"Tolazoline HCl appears to be an effective antagonist for xylazine HCl-ketamine HCl immobilization of wolves."( Xylazine hydrochloride-ketamine hydrochloride immobilization of wolves and its antagonism by tolazoline hydrochloride.
Faggella, AM; Kreeger, TJ; Seal, US, 1986
)
1.21
"Tolazoline Hydrochloride is a pulmonary vasodilator that is used for the treatment of pulmonary hypertension of the newborn. "( Duodenal ulceration: a complication of tolazoline therapy.
Auldist, A; Butt, W; Duncan, A; McDougall, P, 1986
)
1.98

Effects

Tolazoline has dual endothelium-independent vasoactive effects, causing vasoconstriction on isolated rabbit pulmonary arteries, either untreated or precontracted with KCl. Tolazoline is often administered experimentally to lambs without consideration of its pharmacokinetics.

ExcerptReferenceRelevance
"Tolazoline has often been administered experimentally to lambs without consideration of its pharmacokinetics. "( Tolazoline pharmacokinetics in lambs.
Daniel, CH; Gallaher, KJ; Ward, RM; Willes, SR, 1984
)
3.15
"Tolazoline has dual endothelium-independent vasoactive effects, causing vasoconstriction on isolated rabbit pulmonary arteries, either untreated or precontracted with KCl, and vasodilation on those precontracted with NE. "( Dual vasoactive effects of tolazoline on rabbit pulmonary arteries.
Hou, X; Lee, TS, 1996
)
2.03
"Tolazoline has always been administered to infants suffering refractory hypoxemia, but, unfortunately, pulmonary hypertension has not usually been investigated."( Vasodilators in persistent pulmonary hypertension of the newborn: a need for optimal appraisal of efficacy.
Françoise, M; Gouyon, JB, 1992
)
1

Actions

Tolazoline did not lower AaDO2 and OI values, but MABP dropped significantly. Both tolazoline and clonidine produce agonist effects sensitive to histamine H2-receptor antagonism.

ExcerptReferenceRelevance
"Both tolazoline and clonidine produce agonist effects sensitive to histamine H2-receptor antagonism in whole animals and a variety of isolated tissues. "( The histamine-like effects of tolazoline and clonidine:: evidence against direct activity at histamine receptors.
Angus, JA; Kenakin, TP, 1981
)
1.07
"Tolazoline did not lower AaDO2 and OI values, but MABP dropped significantly."( Persistent pulmonary hypertension in high-risk congenital diaphragmatic hernia patients: incidence and vasodilator therapy.
Bos, AP; Hazebroek, FW; Koot, VC; Molenaar, JC; Tibboel, D, 1993
)
1.01

Treatment

Tolazoline treatment of neonates has been reported since 1965. Treatment with tolazoline alone produced significant (P < 0.01) increases in ICP and mean arterial pressure.

ExcerptReferenceRelevance
"If tolazoline treatment did not fulfill the criteria for pulmonary vasodilation, prostacyclin was given by continuous iv infusion at a starting rate of 5 ng/kg/min, followed by 10 ng/kg/min."( Effects of tolazoline and prostacyclin on pulmonary hypertension in infants after cardiac surgery.
Huth, R; Iversen, S; Jüngst, BK; Oelert, H; Schranz, D; Wippermann, C; Zepp, F; Zimmer, B, 1992
)
1.19
"Tolazoline treatment of neonates has been reported since 1965. "( Oliguria and tolazoline pharmacokinetics in the newborn.
Daniel, CH; Kendig, JW; Ward, RM; Wood, MA, 1986
)
2.08
"Treatment with tolazoline alone produced significant (P < 0.01) increases in ICP and mean arterial pressure."( Intracranial pressure reduction by a central alpha-2 adrenoreceptor agonist after subarachnoid hemorrhage.
McCormick, JM; McCormick, PW; Spetzler, RF; Zabramski, JM, 1993
)
0.63

Toxicity

ExcerptReferenceRelevance
"Monensin is extremely toxic to some domestic animals, like the equine species, if they ingest poultry or cattle rations containing the drug."( Effects of some calcium modulators on monensin toxicity.
Martin, T; Mitema, ES; Sangiah, S, 1988
)
0.27
" The oral LD50 values for these species were similar."( Acute, subacute and chronic toxicity/Carcinogenicity of lofexidine.
Beitman, RE; Fontaine, R; Friehe, H; Gibson, JP; Larson, EJ; Tsai, TH, 1982
)
0.26

Pharmacokinetics

The reversal of the sedative and cardiovascular effects following detomidine may not be complete. We have used a chemically specific assay to determine tolazoline pharmacokinetic parameters in lambs after pulse and infusion doses: alpha = 0.

ExcerptReferenceRelevance
" The purpose of our study was to examine the pharmacokinetic and pharmacodynamic characteristics of endobronchial tolazoline to determine the relationship between endobronchial tolazoline administration, plasma concentration, and its effects on the cardiovascular and respiratory systems."( Pharmacokinetics of endobronchial tolazoline administration in dogs.
Barzilay, Z; Ben-Abraham, R; Eyal, O; Ezra, D; Manisterski, Y; Mayan, H; Paret, G; Vardi, A, 1999
)
0.79
" The purpose of our study was to examine the pharmacokinetic and pharmacodynamic characteristics of endotracheal tolazoline in order to determine the relationship between endotracheal tolazoline administration, plasma concentration and its effects on the cardiovascular and respiratory systems."( Endotracheal tolazoline: pharmacokinetics and pharmacodynamics in dogs.
Barzilay, Z; Ben-Abraham, R; Eyal, O; Ezra, D; Gilad, E; Mayan, H; Paret, G, 1999
)
0.88
" The pharmacokinetics and pharmacodynamic effects of tolazoline when administered subsequent to detomidine in the horse were recently reported, although the reversal of the sedative and cardiovascular effects following detomidine may not be complete."( Pharmacokinetics and pharmacodynamic effects of tolazoline following intravenous administration to horses.
Casbeer, HC; Knych, HK, 2013
)
0.9

Bioavailability

ExcerptReferenceRelevance
" In the present study, ketamine-anesthetized Sprague-Dawley rats were exposed to 2450-MHz microwaves at an average power density of 60 mW/cm2 (whole-body specific absorption rate of approximately 14 W/kg) until lethal temperatures were attained."( Tolazoline decreases survival time during microwave-induced lethal heat stress in anesthetized rats.
Chang, KS; Frei, MR; Jauchem, JR, 1996
)
1.74
"The purpose of the study was to evaluate the effect of adding peripheral vasodilators, tolazoline, or papaverine, to transdermal drug delivery vehicles with the goal of improving the tissue bioavailability of transdermally delivered ibuprofen."( Vasomodulation influences on the transdermal delivery of Ibuprofen.
Carter, SG; Riviere, JE; Varadi, G; Veves, A; Zhu, Z, 2013
)
0.61

Dosage Studied

Animals received Prostaglandin E1 (PGE1), Tolazoline (TOL), and Prostacyclin (PGI2) in varying dosages until PVR was reduced or the dosage no longer tolerated. Model parameters were estimated separately for dosing (4 h current-on) and washout (4h current-off) periods in experiments with coadministered vasoactive drugs and controls.

ExcerptRelevanceReference
" Dose-response lines for all the compounds except clonidine were parallel."( Comparison of pre-junctional alpha-adrenoceptors at the neuromuscular junction with vascular post-junctional alpha-receptors in cat skeletal muscle.
Malta, E; McPherson, GA; Raper, C, 1979
)
0.26
" When YOH was used as an anesthetic antagonist at dosage of 20 mg/kg, 20% mortality was observed and was attributable to acute respiratory arrest."( Antagonism of ketamine-xylazine anesthesia in rats by administration of yohimbine, tolazoline, or 4-aminopyridine.
Komulainen, A; Olson, ME, 1991
)
0.51
" Using a dosage of 3-5 mg/kg there is a marked negative effect on the cardio-vascular system."( [The antagonism of ketamine/xylazine anesthesia ("Hellabrunn mixture") in wild zoo ruminants].
Erhardt, W; Hafner, S; Halm, S; von Hegel, G; Wiesner, H, 1989
)
0.28
" IBI at 10(-6) M shifted the dose-response curve of phenylephrine to the right with reduction in maxima."( Paradoxical effects of isothiocyanate analog of tolazoline on rat aorta and human platelets.
Feller, DR; Hamada, A; Miller, DD; Patil, PN; Shams, G; Venkataraman, BV, 1989
)
0.53
" Intravenously administered PGE2 at a five times higher dosage failed to significantly alter net water and electrolyte fluxes."( Central nervous system influence of prostaglandin E2 on jejunal water and electrolyte transport in conscious dogs.
Bueno, L; Primi, MP, 1986
)
0.27
"0 mg/kg) resulted in a 3-10-fold shift to the right in the clonidine dose-response curve."( Effects of clonidine on operant behavior and electric shock titration in the squirrel monkey: effects of alpha 2-adrenoreceptor antagonism.
McKearney, JW, 1983
)
0.27
" Dosing protocol may be important in determining the overall circulatory response to a given drug dose."( Circulatory effects of tolazoline and prostacyclin (PGI2) in chronically instrumented lambs.
Drummond, WH; Webb, IB; Williams, BJ, 1984
)
0.58
" Animals then received Prostaglandin E1 (PGE1), Tolazoline (TOL), and Prostacyclin (PGI2) in varying dosages until PVR was reduced or the dosage no longer tolerated."( Comparative studies on the hemodynamic effects of prostaglandin E1 prostacyclin, and tolazoline upon elevated pulmonary vascular resistance in neonatal swine.
Elliott, RB; Elliott, RL; Neutze, JM; Starling, MB, 1981
)
0.74
" Model parameters were estimated separately for dosing (4 h current-on) and washout (4 h current-off) periods in experiments with coadministered vasoactive drugs [tolazoline (vasodilator) and norepinephrine (vasoconstrictor)] and controls (lidocaine alone)."( Model describing transdermal iontophoretic delivery of lidocaine incorporating consideration of cutaneous microvascular state.
Riviere, JE; Williams, PL, 1993
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
alpha-adrenergic antagonistAn agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
vasodilator agentA drug used to cause dilation of the blood vessels.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
imidazolesA five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thyroid stimulating hormone receptorHomo sapiens (human)Potency15.84890.001318.074339.8107AID926; AID938
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency15.84890.00207.533739.8107AID891
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency2.75130.005612.367736.1254AID624032
lamin isoform A-delta10Homo sapiens (human)Potency0.17780.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)2.10000.00021.874210.0000AID167199
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)Ki0.18000.00000.929610.0000AID35187
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)Ki0.18000.00000.970810.0000AID35187
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)Ki0.18000.00000.937510.0000AID35187
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)2.10000.00021.270410.0000AID167199
5-hydroxytryptamine receptor 1DHomo sapiens (human)Ki10.00000.00010.808710.0000AID238273; AID4618
5-hydroxytryptamine receptor 1BHomo sapiens (human)Ki10.00000.00010.54859.2100AID238272; AID4249
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)2.10000.00001.819410.0000AID167199
Trace amine-associated receptor 1Homo sapiens (human)Ki1.64000.50001.07001.6400AID714266
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Kd2.18780.00020.52667.5858AID196984
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)Kd1.51360.00020.62779.3325AID196987
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)Kd1.51360.00020.62779.3325AID196987
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)Kd1.51360.00020.62779.3325AID196987
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)Kd2.18780.00020.89627.5858AID196984
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Kd2.18780.00020.51397.5858AID196984
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (49)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1DHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 1DHomo sapiens (human)
regulation of locomotion5-hydroxytryptamine receptor 1DHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 1DHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1DHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1DHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1DHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1DHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 1BHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1BHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of gamma-aminobutyric acid secretion5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of serotonin secretion5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of synaptic transmission, GABAergic5-hydroxytryptamine receptor 1BHomo sapiens (human)
response to cocaine5-hydroxytryptamine receptor 1BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 1BHomo sapiens (human)
drinking behavior5-hydroxytryptamine receptor 1BHomo sapiens (human)
response to ethanol5-hydroxytryptamine receptor 1BHomo sapiens (human)
bone remodeling5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1BHomo sapiens (human)
response to mineralocorticoid5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 1BHomo sapiens (human)
cellular response to alkaloid5-hydroxytryptamine receptor 1BHomo sapiens (human)
cellular response to xenobiotic stimulus5-hydroxytryptamine receptor 1BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 1BHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentration5-hydroxytryptamine receptor 1BHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of synaptic vesicle exocytosis5-hydroxytryptamine receptor 1BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1BHomo sapiens (human)
G protein-coupled receptor signaling pathwayTrace amine-associated receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1DHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1DHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1BHomo sapiens (human)
voltage-gated calcium channel activity involved in regulation of presynaptic cytosolic calcium levels5-hydroxytryptamine receptor 1BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1BHomo sapiens (human)
G protein-coupled receptor activityTrace amine-associated receptor 1Homo sapiens (human)
trace-amine receptor activityTrace amine-associated receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1DHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1DHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1DHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1DHomo sapiens (human)
endoplasmic reticulum5-hydroxytryptamine receptor 1BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1BHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 1BHomo sapiens (human)
calyx of Held5-hydroxytryptamine receptor 1BHomo sapiens (human)
serotonergic synapse5-hydroxytryptamine receptor 1BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 1BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1BHomo sapiens (human)
plasma membraneTrace amine-associated receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (48)

Assay IDTitleYearJournalArticle
AID167202Inhibition of specific [3H]-clonidine binding (0.4 nM) to rat brain membranes alpha-2 adrenoceptor; 2.8*10e-71984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID35187Displacement of [3H]clonidine from Alpha-2 adrenergic receptor of rat brain membranes1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs.
AID1145606Octanol-aqueous phase partition coefficient, log P of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID4249Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand1998Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13
Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation.
AID238273Binding affinity towards human 5-hydroxytryptamine 1D receptor2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
2-(Anilino)imidazolines and 2-(benzyl)imidazoline derivatives as h5-HT1D serotonin receptor ligands.
AID666536Antiarrhythmic activity in iv dosed adrenaline-induced Wistar rat arrhythmia model assessed as protection against mortality administered 15 mins prior to barium chloride-challenge2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
Antiarrhythmic properties of phenylpiperazine derivatives of phenytoin with α₁-adrenoceptor affinities.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID235864Index of alpha1/alpha2 adrenoceptor antagonist selectivity at post junctional vascular sites in vivo.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID36427Inhibition of specific [3H]prazosin binding (0.2 nM) to rat brain membranes alpha-1 adrenergic receptor; 2.1*10e-61984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID235865Index of alpha1/alpha2 adrenoceptor antagonist selectivity at pre and postsynaptic sites in vitro.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1145608Drug absorption in anesthetized rat colon at pH 6.81977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID196987Antagonist activity against B-HT 933-induced alpha-2-adrenoceptor-mediated vasoconstriction in pithed normotensive rats1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID235866Index of alpha1/alpha2 adrenoceptor binding selectivity.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID714266Displacement of (S)-4-(2,4-difluorophenyl-3-tritio) -4,5-dihydro-2-oxazolamine from human TAAR1 receptor expressed in HEK293 cells after 90 mins by beta counting analysis2012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Optimisation of imidazole compounds as selective TAAR1 agonists: discovery of RO5073012.
AID196984Antagonist activity against phenylephrine-induced alpha1- adrenoceptor mediated vasoconstriction in pithed normotensive rats. 1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID666535Antiarrhythmic activity in iv dosed Wistar rat assessed as protection against adrenaline-induced bigeminy administered 15 mins prior to adrenaline-challenge2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
Antiarrhythmic properties of phenylpiperazine derivatives of phenytoin with α₁-adrenoceptor affinities.
AID714267Selectivity ratio of Ki for human adrenergic alpha2A receptor expressed in CHL cells to Ki for human TAAR1 receptor2012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Optimisation of imidazole compounds as selective TAAR1 agonists: discovery of RO5073012.
AID1145610Dissociation constant, pKa of the compound at pH 6.81977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID437168Antiarrhythmic activity against adrenaline-induced arrhythmia in iv dosed rat assessed as inhibition of cardiac rhythm disturbance administered 15 mins before adrenaline challenge2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Design, synthesis and pharmacological evaluation of new 1-[3-(4-arylpiperazin-1-yl)-2-hydroxy-propyl]-3,3-diphenylpyrrolidin-2-one derivatives with antiarrhythmic, antihypertensive, and alpha-adrenolytic activity.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID166854Antagonist activity against norepinephrine-induced alpha-2-adrenoceptor-mediated vasoconstriction of rabbit isolated pulmonary artery.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID1145607Octanol-aqueous phase distribution coefficient, log D of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID4618Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand1998Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13
Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID233042Binding Selectivity was determined [Selectivity = Ki against h5-HT1B receptor / Ki against h5-HT1D receptor]; not determined1998Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13
Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID666534Antiarrhythmic activity in iv dosed Wistar rat assessed as protection against adrenaline-induced extrasystoles administered 15 mins prior to adrenaline-challenge2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
Antiarrhythmic properties of phenylpiperazine derivatives of phenytoin with α₁-adrenoceptor affinities.
AID167199Inhibition of specific [3H]-prazosin binding (0.2 nM) to rat brain membranes alpha1 adrenoceptor; 2.1*10e-61984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1145613Drug absorption in rat small intestine1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID1145612Dissociation constant, pKa of the compound at pH 5.31977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID238272Binding affinity towards human 5-hydroxytryptamine 1B receptor2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
2-(Anilino)imidazolines and 2-(benzyl)imidazoline derivatives as h5-HT1D serotonin receptor ligands.
AID666540Antiarrhythmic activity in iv dosed Wistar rat assessed as protection against adrenaline-induced arrhythmia administered 15 mins prior to adrenaline-challenge2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
Antiarrhythmic properties of phenylpiperazine derivatives of phenytoin with α₁-adrenoceptor affinities.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346159Human alpha2C-adrenoceptor (Adrenoceptors)1998Biochemical pharmacology, Apr-01, Volume: 55, Issue:7
Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding.
AID1346058Human alpha2B-adrenoceptor (Adrenoceptors)1998Biochemical pharmacology, Apr-01, Volume: 55, Issue:7
Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding.
AID1346049Human alpha2A-adrenoceptor (Adrenoceptors)1998Biochemical pharmacology, Apr-01, Volume: 55, Issue:7
Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,069)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990931 (87.09)18.7374
1990's88 (8.23)18.2507
2000's30 (2.81)29.6817
2010's19 (1.78)24.3611
2020's1 (0.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 49.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index49.48 (24.57)
Research Supply Index7.06 (2.92)
Research Growth Index4.08 (4.65)
Search Engine Demand Index83.05 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (49.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials25 (2.20%)5.53%
Reviews41 (3.62%)6.00%
Case Studies82 (7.23%)4.05%
Observational0 (0.00%)0.25%
Other986 (86.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]